Streetbeat News

Products Services

AGEN

Agenus Inc. (NASDAQ:AGEN) will hold a Type B End-of-Phase 2 meeting with the FDA in July to discuss its BOT/BAL therapy for relapsed/refractory metastatic colorectal cancer. The meeting aims to expedite the development and support a future BLA submission.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:40 am

LILM

Lilium N.V. (NASDAQ:LILM) has started construction of an advanced test facility for the Lilium Jet in partnership with SEGULA Technologies. The facility, located near Munich, Germany, will be operational by late Summer 2024 and will be used for integration and certification testing of the Lilium Jet.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:38 am

REE

REE Automotive announced that its P7-C electric trucks and platforms have been approved for a $30,000 incentive per vehicle in Massachusetts.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:38 am

BIIB

IONS

Ionis Pharmaceuticals and Biogen have announced the discontinuation of the development of BIIB105 based on data from a Phase 1/2 study.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:36 am

AXGN

Axogen has initiated the rolling submission process with the FDA for a Biologics License Application (BLA) for its Avance Nerve Graft. The company expects to complete the BLA filing by Q3 2024 and anticipates approval around mid-2025.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:34 am

JNJ

Johnson & Johnson (NYSE:JNJ) announced its acquisition of Proteologix, Inc. for $850 million in cash, with potential milestone payments. Proteologix specializes in bispecific antibodies for immune-mediated diseases, including atopic dermatitis and asthma.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:33 am

MTNB

Matinas BioPharma presented new in vitro data at TIDES USA 2024, demonstrating their LNC platform's ability to deliver small oligonucleotides.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:32 am

ENTO

First Wave BioPharma has rebranded to Entero Therapeutics and is advancing towards a Phase 3 clinical trial for its lead asset, Latiglutenase, aimed at treating celiac disease. The company's stock will trade under the new ticker symbol ENTO starting May 17, 2024.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:30 am

DOW

Dow (NYSE:DOW) has announced the start-up of its propylene glycol capacity expansion at its facility in Thailand, increasing capacity by 80,000 tons per year to a total of 250,000 tons per year. This makes the facility the largest in Asia Pacific.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:28 am

DOW

Dow (NYSE:DOW) has completed the mechanical setup of its new VORATRON™ Polyurethanes Systems adhesive and gap filler production line in Ahlen, Germany. This expansion will increase the production capacity tenfold to meet the growing demand in the e-mobility segment, particularly for electric vehicle battery assembly solutions.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 11:25 am